BioScience Health InnovationsBHIC -0.48%45 PB Ratio is 29.25 as of Jun. 26, 2026, which is 96% below its 10-year median of 684.21. GuruFocus rates BHIC with a GF Score™ of 45/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 611 Healthcare Providers & Services companies, BioScience Health Innovations ranks worse than 98.04% on this metric.
The historical rank and industry rank for BioScience Health Innovations's PB Ratio or its related term are showing as below:
BHIC'
s PB Ratio Range Over the Past 10 Years
Min: 14.53 Med: 684.21 Max: 52000
Current: 28.86
During the past 7 years, BioScience Health Innovations's highest PB Ratio was 52000.00. The lowest was 14.53. And the median was 684.21.
BHIC's PB Ratio is ranked worse than 98.04% of 611
companies
in the Healthcare Providers & Services industry
Industry Median: 1.98
vs BHIC: 28.86
During the past 12 months, BioScience Health Innovations's average Book Value Per Share Growth Rate was 28.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 138.10% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of BioScience Health Innovations was 138.10% per year. The lowest was 115.40% per year. And the median was 126.75% per year.
Back to Basics: PB Ratio
BioScience Health Innovations (OTCPK:BHIC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
BioScience Health Innovations PB Ratio Related Terms
BioScience Health Innovations PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's PB Ratio distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's PB Ratio falls into.
BioScience Health Innovations PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
BioScience Health Innovations (BHIC) has a PB Ratio of 29.25 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioScience Health Innovations and its competitors. This is 96% below median its historical median of 684.21. Over the past decade, BioScience Health Innovations' PB Ratio has ranged from 14.53 to 52,000.00. According to the industry distribution chart, BioScience Health Innovations ranks #599 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 98%.
Is BioScience Health Innovations' PB Ratio too high?
BioScience Health Innovations' current PB Ratio of 29.25 is 96% below median its 10-year median of 684.21. Over the past 10 years, this metric has ranged from a low of 14.53 to a high of 52,000.00. The Healthcare Providers & Services industry median PB Ratio is 1.98. BioScience Health Innovations' value of 29.25 is 1377.3% above this industry median. Based on the distribution chart, BioScience Health Innovations ranks #599 out of 611 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' PB Ratio compare to PETS and SHFH?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #599 out of 611 companies for PB Ratio. This places BioScience Health Innovations in the lower half of its industry. The industry median PB Ratio is 1.98. BioScience Health Innovations' value of 29.25 is 1377.3% above this benchmark. Historically, BioScience Health Innovations' own PB Ratio has ranged from 14.53 to 52,000.00 over the past decade. While the company's 10-year median is 684.21 vs. the industry median of 1.98, BioScience Health Innovations has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.98, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current PB Ratio of 29.25 is 1377.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current PB Ratio is 29.25, which is 96% below median its own 10-year median of 684.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.33 — trading 97.4% below its estimated fair value. The current PB Ratio is 29.25, which is 96% below median its 10-year median of 684.21 and 1377.3% above the Healthcare Providers & Services industry median of 1.98. BioScience Health Innovations' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current PB Ratio is 29.25 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.33 is trading 97.4% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
PB Ratio: 29.25 (96% below median its 10-year median of 684.21)
GF Value™: $164.84 vs. price of $4.33 (97.4% below fair value)
Industry Position: 1377.3% above the Healthcare Providers & Services median (#599 of 611)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
45GF Score
Get the complete analysis for BHIC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
